Premium
Bulleyaconitine A prevents Ti particle‐induced osteolysis via suppressing NF‐κB signal pathway during osteoclastogenesis and osteoblastogenesis
Author(s) -
Zhang Liwei,
Feng Mingxuan,
Li Zhiyan,
Zhu Min,
Fan Yongyong,
Chu Binxiang,
Yuan Chiting,
Chen Lihua,
Lv Haiyan,
Hong Zhenghua,
Hong Dun
Publication year - 2018
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.26508
Subject(s) - osteolysis , bone resorption , osteoclast , osteoblast , chemistry , nf κb , in vivo , resorption , microbiology and biotechnology , cancer research , signal transduction , osteoporosis , endocrinology , medicine , in vitro , biology , biochemistry , dentistry
Balanced bone resorption and bone formation are vital for bone homeostasis. Excessive osteoclastic bone resorption in this process can cause a variety of bone disorders including osteoporosis, aseptic prosthetic loosening and tumor associated bone destruction. Bulleyaconitine A (BLA) is a natural compound that has been widely used for pain treatment but its role in osteolysis has not yet been investigated. In this study, we verified for the first time that BLA inhibited osteoclast formation, the mRNA expression of osteoclast‐related genes and osteoclastic bone resorption by inhibiting NF‐κB signal pathway and downstream NFATc1 expression. Meanwhile, BLA had a stimulatory effect in osteoblast differentiation and mineralization. Furthermore, BLA showed preventive effect in Ti particle‐induced osteolysis model in vivo. Together, all our data demonstrated that BLA suppressed osteoclastogenesis and promoted osteoblastogenesis via suppressing NF‐κB signal pathway and could be an alternative therapeutic choice against bone loss.